Literature DB >> 20634637

Pros and cons of dexamethasone suppression test for screening of subclinical Cushing's syndrome in patients with adrenal incidentalomas.

G Reimondo1, B Allasino, S Bovio, L Saba, A Ardito, A Angeli, M Terzolo.   

Abstract

The results of dexamethasone suppression tests (DST) in the screening of subclinical hypercortisolism are not readily comparable. Aim of the present study was to review the effectiveness of overnight 1-mg DST and 8-mg DST to look for functional autonomy of clinically inapparent adrenal adenomas. Sixty-eight consecutive patients with clinically inapparent adrenal adenomas were enrolled. All patients underwent 1-mg DST. The 8-mg DST was performed in the 11 patients who had post 1-mg DST cortisol >138 nmol/l and in 11 patients who had post 1-mg DST cortisol between 50 and 138 nmol/l. The a priori probability to have autonomous cortisol secretion was defined by the presence of at least two alterations of the hypothalamic-pituitary-adrenal axis among reduced ACTH concentrations, elevated urinary free cortisol (UFC) or elevated midnight serum cortisol. Cortisol levels >138 nmol/l after the 1-mg DST increases the post-test probability of adrenal functional autonomy to 55%, whereas cortisol levels <50 nmol/l reduce the post-test probability to 8%. Cortisol levels recorded after the 8-mg DST were nonsignificantly lower than after the 1-mg DST and all the patients with cortisol >138 nmol/l after the 1-mg DST maintained cortisol above this cut-point. The 1-mg DST should be considered as the more effective test to detect autonomous cortisol secretion by a clinically inapparent adrenal adenoma when cortisol levels are >138 nmol/l, while cortisol levels <50 nmol/l reduce remarkably the post-test probability of this event. The 8-mg DST seems to replicate by large the results of the 1-mg DST.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20634637     DOI: 10.1007/BF03346701

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  34 in total

1.  Preclinical Cushing's syndrome in adrenal "incidentalomas": comparison with adrenal Cushing's syndrome.

Authors:  M Reincke; J Nieke; G P Krestin; W Saeger; B Allolio; W Winkelmann
Journal:  J Clin Endocrinol Metab       Date:  1992-09       Impact factor: 5.958

Review 2.  The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states.

Authors:  J Newell-Price; P Trainer; M Besser; A Grossman
Journal:  Endocr Rev       Date:  1998-10       Impact factor: 19.871

3.  Glucocorticoid sensitivity in young healthy individuals: in vitro and in vivo studies.

Authors:  Rosangela Soares Chriguer; Lucila Leico Kagohara Elias; Ivan Moreira da Silva; Jose Gilberto Henriques Vieira; Ayrton Custodio Moreira; Margaret de Castro
Journal:  J Clin Endocrinol Metab       Date:  2005-08-09       Impact factor: 5.958

4.  Long-term follow-up study of patients with adrenal incidentalomas.

Authors:  Rossella Libè; Chiara Dall'Asta; Laura Barbetta; Andrea Baccarelli; Paolo Beck-Peccoz; Bruno Ambrosi
Journal:  Eur J Endocrinol       Date:  2002-10       Impact factor: 6.664

5.  Management of the clinically inapparent adrenal mass ("incidentaloma").

Authors:  Melvin M Grumbach; Beverly M K Biller; Glenn D Braunstein; Karen K Campbell; J Aidan Carney; Paul A Godley; Emily L Harris; Joseph K T Lee; Yolanda C Oertel; Mitchell C Posner; Janet A Schlechte; H Samuel Wieand
Journal:  Ann Intern Med       Date:  2003-03-04       Impact factor: 25.391

6.  Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience.

Authors:  Amir H Hamrahian; Adriana G Ioachimescu; Erick M Remer; Gaspar Motta-Ramirez; Hari Bogabathina; Howard S Levin; Sethu Reddy; Inderbir S Gill; Allan Siperstein; Emmanuel L Bravo
Journal:  J Clin Endocrinol Metab       Date:  2004-11-30       Impact factor: 5.958

7.  Partially autonomous cortisol secretion by incidentally discovered adrenal adenomas.

Authors:  H Lavoie; A Lacroix
Journal:  Trends Endocrinol Metab       Date:  1995-08       Impact factor: 12.015

8.  Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink?

Authors:  T J Cawood; P J Hunt; D O'Shea; D Cole; S Soule
Journal:  Eur J Endocrinol       Date:  2009-05-13       Impact factor: 6.664

9.  Subclinical hypercortisolism among outpatients referred for osteoporosis.

Authors:  Iacopo Chiodini; Maria Lucia Mascia; Silvana Muscarella; Claudia Battista; Salvatore Minisola; Maura Arosio; Stefano Angelo Santini; Giuseppe Guglielmi; Vincenzo Carnevale; Alfredo Scillitani
Journal:  Ann Intern Med       Date:  2007-10-16       Impact factor: 25.391

10.  2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mansia; Guy De Backer; Anna Dominiczak; Renata Cifkova; Robert Fagard; Giuseppe Germano; Guido Grassi; Anthony M Heagerty; Sverre E Kjeldsen; Stephane Laurent; Krzysztof Narkiewicz; Luis Ruilope; Andrzej Rynkiewicz; Roland E Schmieder; Harry A Struijker Boudier; Alberto Zanchetti
Journal:  Blood Press       Date:  2007       Impact factor: 2.835

View more
  2 in total

Review 1.  Cushing's syndrome: from physiological principles to diagnosis and clinical care.

Authors:  Hershel Raff; Ty Carroll
Journal:  J Physiol       Date:  2015-01-05       Impact factor: 5.182

2.  Mifepristone reduces insulin resistance in patient volunteers with adrenal incidentalomas that secrete low levels of cortisol: a pilot study.

Authors:  Miguel Debono; Rita Chadarevian; Richard Eastell; Richard J Ross; John Newell-Price
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.